c-FLIP, a master anti-apoptotic regulator

dc.contributor.authorSafa, A. R.
dc.contributor.departmentDepartment of Pharmacology and Toxicology, IU School of Medicineen_US
dc.date.accessioned2016-09-07T18:05:49Z
dc.date.available2016-09-07T18:05:49Z
dc.date.issued2012-10
dc.description.abstractCellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) is a master anti-apoptotic regulator and resistance factor that suppresses tumor necrosis factor-α (TNF-α), Fas-L, and TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, as well as apoptosis triggered by chemotherapy agents in malignant cells. c-FLIP is expressed as long (c-FLIP(L)), short (c-FLIP(S)), and c-FLIP(R) splice variants in human cells. c-FLIP binds to FADD and/or caspase-8 or -10 and TRAIL receptor 5 (DR5) in a ligand-dependent and -independent fashion and forms an apoptosis inhibitory complex (AIC). This interaction in turn prevents death-inducing signaling complex (DISC) formation and subsequent activation of the caspase cascade. c-FLIP(L) and c-FLIP(S) are also known to have multifunctional roles in various signaling pathways, as well as activating and/or upregulating several cytoprotective and pro-survival signaling proteins including Akt, ERK, and NF-kB. Upregulation of c-FLIP has been found in various tumor types, and its silencing has been shown to restore apoptosis triggered by cytokines and various chemotherapeutic agents. Hence, c-FLIP is an important target for cancer therapy. For example, small interfering RNAs (siRNAs) that specifically knockdown the expression of c-FLIP(L) in diverse human cancer cell lines augmented TRAIL-induced DISC recruitment and increased the efficacy of chemotherapeutic agents, thereby enhancing effector caspase stimulation and apoptosis. Moreover, small molecules causing degradation of c-FLIP as well as decreasing mRNA and protein levels of c-FLIP(L) and c-FLIP(S) splice variants have been found, and much effort is focused on developing other c-FLIP-targeted cancer therapies. This review focuses on (1) the anti-apoptotic role of c-FLIP splice variants in preventing apoptosis and inducing cytokine and chemotherapy drug resistance, (2) the molecular mechanisms and factors that regulate c-FLIP expression, and (3) modulation of c-FLIP expression and function to eliminate cancer cells or increase the efficacy of anticancer agents. This article is part of a Special Issue entitled "Apoptosis: Four Decades Later".en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationSafa, A. R. (2012). c-FLIP, A MASTER ANTI-APOPTOTIC REGULATOR. Experimental Oncology, 34(3), 176–184.en_US
dc.identifier.issn1812-9269en_US
dc.identifier.urihttps://hdl.handle.net/1805/10873
dc.language.isoen_USen_US
dc.publisherMorionen_US
dc.relation.journalExperimental Oncologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectApoptosisen_US
dc.subjectCASP8 and FADD-Like Apoptosis Regulating Proteinen_US
dc.subjectmetabolismen_US
dc.subjectNeoplasmsen_US
dc.subjectdrug therapyen_US
dc.subjectSignal Transductionen_US
dc.titlec-FLIP, a master anti-apoptotic regulatoren_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms771427.pdf
Size:
448.87 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: